JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9
Larimar Therapeutics Inc LRMR
$3.49
▼ -0.85%
($-0.03)
Open
$3.52
Prev Close
$3.52
Day Range
$3.43 – $3.57
52W Range
$1.80 – $6.42
Market Cap
$365.67M
Beta
0.85
EPS (TTM)
$-2.08
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-19 |
| Shares Out. | 103,880,000 |
| Website | larimartx.com/ ↗ |
| Phone | 13026587581 |
Larimar Therapeutics Inc is a publicly traded company under the ticker symbol LRMR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-05-01)
📰 Latest News for LRMR
Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12
Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate
Larimar: Q1 Earnings Snapshot
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update